Overview

To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Veldicitumab Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)

Status:
Not yet recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
This is a single-center, open-label, dose-escalation phase I clinical study.This study aimed to evaluate the safety, tolerability, pharmacokinetics and preliminary clinical efficacy of RC48-ADC combined with RC98 in subjects with advanced gastric cancer.Which will provide a reference basis for dose confirmation in subsequent clinical studies.
Phase:
Phase 1
Details
Lead Sponsor:
RemeGen Co., Ltd.